Showing results for:
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Ifex® Ifosfamide
Imatinib mesylate is FDA approved to treatNewly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phasePatients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapyAdult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapyAdult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved testAdult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1- PDGFRα fusion kinase negative or unknown.
Gleevec® Imatinib mesylate
Imetelstat is FDA approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Rytelo Imetelstat
Inotuzumab ozogamicin is FDA approved for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
Besponsa® Inotuzumab Ozogamicin
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances. Interferon alfa-2a is FDA approved to treat people who have hairy cell leukemia and Philadelphia chromosome positive chronic myeloid leukemia who are minimally pretreated (within 1 year of diagnosis). It may cause a temporary loss of hair. After treatment has ended, normal hair growth should return.
Roferon®-A Interferon alfa-2a
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances.Interferon alfa-2b is FDA approved to treat people who have hairy cell leukemia, polycythemia vera and aggressive follicular non-Hodgkin lymphoma.
Intron® A Interferon alfa-2b BESREMi®
Isatuximab-irfc is FDA approvedIn combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Sarclisa® Isatuximab-irfc
Ivosidenib is FDA approved for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test in:Newly diagnosed acute myeloid leukemia (AML)In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy Relapsed or refractory AMLFor the treatment of adult patients with relapsed or refractory AMLRelapsed or refractory myelodysplastic syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes
Tibsovo® Ivosidenib
Ixazomib is FDA approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
NINLARO® Ixazomib
Lenalidomide is FDA approved to treat patients with:Multiple myeloma, in combination with dexamethasoneMultiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalitiesMantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib Previously treated follicular lymphoma (FL), in combination with a rituximab productPreviously treated marginal zone lymphoma (MZL), in combination with a rituximab product Limitations of Use: Revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials
Revlimid® Lenalidomide
Leucovorin is an FDA-approved drug similar to the vitamin folic acid. It protects healthy cells from the effects of methotrexate while allowing methotrexate to enter and kill cancer cells.Levoleucovorin (Fusilev®) is a form of leucovorin that is given intravenously (IV).
Folinic acid Leucovorin Levoleucovorin Fusilev®
Linvoseltamab-gcpt is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Lynozyfic™ Linvoseltamab-gcpt
Liposomal doxorubicin is FDA approved for use in combination with bortezomib to treat patients with myeloma who have not previously received bortezomib and have received at least one prior therapy. See the FDA announcement about drug shortage of Doxil.
Doxil® Liposomal doxorubicin
Lisocabtagene maraleucel is indicated for the treatment ofAdult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or Relapsed or refractory disease after two or more lines of systemic therapy. Limitations of Use: Lisocabtagene maraleucel is not indicated for the treatment of patients with primary central nervous system lymphoma.Adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).Adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
Breyanzi® Lisocabtagene maraleucel
Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy.
CeeNU® CCNU Lomustine
Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Zynlonta™ Loncastuximab tesirine-lpyl
Luspatercept-aamt is FDA approved for the treatment of:Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Limitations of Use: Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Reblozyl® Luspatercept-aamt
Mechlorethamine is FDA approved to treat people who have Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera and mycosis fungoides.
Mustargen® nitrogen mustard Mechlorethamine
Mechlorethamine gel is FDA approved for the treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Valchlor® Mechlorethamine gel
U.S. Food and Drug Administration (FDA) has granted approval of EVOMELA for use in two indications:Use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma (MM)For the palliative treatment of patients with MM for whom oral therapy is not appropriate.This is the first product to be FDA-approved for the high-dose conditioning indication in MM.
Evomela™ Melphalan hydrochloride
Mercaptopurine is FDA approved to treat people who have acute lymphoblastic leukemia as part of a combination regimen.
Purinethol® 6-MP Purixan® Mercaptopurine
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Rheumatrex® Trexall® Methotrexate
Rydapt is FDA approved for the treatment of adult patients with:Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.Limitations of Use:RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Rydapt® Midostaurin
Mitomycin is FDA approved to treat people who have advanced adenocarcinoma of the stomach or pancreas in combination with other approved chemotherapeutic agents and as palliative treatment when other treatments have failed. This medication is sometimes prescribed for other uses such as bladder and lung cancer. Mitomycin sometimes causes a temporary loss of hair. After treatment has ended, normal hair growth should return.
Mutamycin® Mitomycin
Mitoxantrone is FDA approved in combination with other approved drug(s) indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. Mitoxantrone is a dark blue solution that may cause urine to appear blue-green. It may also cause the whites of the eyes to turn a blue color. These effects are normal and last for only 1 or 2 days after each dose is given. This medicine often causes a temporary loss of hair. After treatment with mitoxantrone has ended, normal hair growth should return.
Novantrone® Mitoxantrone
Mogamulizumab is FDA approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Poteligeo® Mogamulizumab
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Momelotinib Ojjaara
Mosunetuzumab-axgb is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mosunetuzumab-axgb Lunsumio™
Moxetumomab pasudotox-tdfk is FDA approved for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Lumoxiti® Moxetumomab pasudotox-tdfk
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Arranon® Nelarabine
Tasigna® is FDA approved for the treatment ofAdult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.Danziten™ is FDA approved for the treatment ofAdult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.Eligible newly diagnosed patients with Ph+ CML-Chronic Phase who have received nilotinib for a minimum of 3 years and have achieved a sustained molecular response (MR4.5) and patients with Ph+ CML-Chronic Phase resistant or intolerant to imatinib who have received nilotinib for at least 3 years and have achieved a sustained molecular response (MR4.5) may be considered for treatment discontinuation.
Tasigna® Nilotinib
Nivolumab is FDA approved for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Opdivo® Nivolumab
Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Aucatzyl® Obecabtagene autoleucel
Obinutuzumab is FDA-approved In combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).In combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.In combination with chemotherapy followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.
Gazyva® Obinutuzumab
Ofatumumab is FDA approved For the treatment of patients who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
Arzerra® Ofatumumab
Olutasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Olutasidenib Rezlidhia™
Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).The effectiveness of omacetaxine mepesuccinate was evaluated using a combined group of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with omacetaxine mepesuccinate.
Synribo® Omacetaxine mepesuccinate
Oomidubicel-onlv is indicated for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
Omidubicel-onlv Omisirge®
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Vonjo™ Pacritinib